

## Treanda - (25,100 mg/Vial; Powder, Infusion)

<b>Generic Name</b>	BENDAMUSTINE HYDROCHLORIDE	<b>Innovator</b>	Cephalon
<b>Dosage</b>	25,100 mg/Vial; Powder, Infusion	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	More Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	More Than 5
<b>Final Approvals</b>	More Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	treatment of patients with chronic lymphocytic leukemia ("CLL") and patients with indolent B-cell non-Hodgkin's lymphoma ("NHL") that has progressed during or within six months of treatment with rituximab ora rituximab-containing regimen.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Treanda - (90 mg/ml, 0.5 ml and 2ml in single dose vials)

<b>Generic Name</b>	BENDAMUSTINE HYDROCHLORIDE	<b>Innovator</b>	None
<b>Dosage</b>	90 mg/ml, 0.5 ml and 2ml in single dose vials	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Indicated for the treatment of patients with chronic lymphocytic leukemia ("CLL") and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma ("NHL") that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.